Pasquale Rescigno

Dr. Pasquale Rescigno is a researcher at Newcastle University, focusing on advanced urological cancers including prostate cancer, renal cell carcinoma, and urothelial carcinoma. His work spans clinical trials, biomarker development, and translational research.

• Key collaborations: Meet-URO network, AIOM consensus group
• Clinical trial involvement: RE-AKT trial, ARON-2 study, REGAL registry

Research interests include:

• Immunotherapy: Mechanisms of resistance and response prediction in renal cell carcinoma
• Biomarkers: Red blood cell-based scores, sodium levels, and tumor microenvironment characterization
• Precision Medicine: PARP/ATR inhibitors in DNA repair-deficient prostate cancers
• Geriatric Oncology: Functional assessment in elderly prostate cancer patients

Recent article trends focus on:

• Immune checkpoint inhibitors in metastatic settings
• Multi-omics approaches to prognostication
• Real-world evidence for treatment optimization

Active in the Meet-URO research network, contributing to prospective studies on:

• Clinical decision-making (ADHERE study)
• Imaging advancements (PSMA-PET/CT in renal cancer)
• Novel therapeutic targets (STING agonists, B7-H3)